Natalia A. Lapkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalia A. Lapkina has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Andrey A. Baranov
Yaroslavl State Medical University
21 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
11 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
8 shared publications - Alexander S. Artyuhov
N.I. Pirogov Russian National Research Medical University
7 shared publications - Andrey E. Karateev
V.A. Nasonova Research Institute of Rheumatology
6 shared publications - Natalia E. Abaytova
Yaroslavl State Medical University
5 shared publications
Latest Publications
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Cytokine clusters in rheumatoid arthritis: pathogenetic parallels
An imbalance in the production of pro- and anti-inflammatory cytokines plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Seropositivity for IgM rheumatoid factor (RF) and/or antibodies to cyclic citrullinated peptides (ACCP) determines disease subtypes. The aim of the study . To conduct a cluster analysis of the profile of pro- and anti-inflammatory cytokines detected in the blood serum of RA patients with an advanced stage of the disease in comparison with healthy individuals, the presence of IgM RF and ACCP in patients. Materials and methods . The study included 154 RA patients (41 men and 113 women of middle age 56.0 [50.0; 64.0] years), disease duration 9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM RF and/or 106 (68.8 %) ACCP with moderate or high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. Serum concentrations of interleukins (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ) and soluble CD 40 ligand (sCD 40L) were determined using multiplex technology. Hierarchical clustering of cytokines was performed in 20 healthy individuals and RA patients using Ward’s method. In RA, a comparison was made between seronegative and seropositive groups for IgM RF/ACCP. Results . In healthy individuals, the cytokine network exhibited a physiological organization. Cytokines were grouped into compact, well-defined modules with minimal cross-links between individual components. A dominant proinflammatory core of cytokines was absent, and a balanced cytokine network was observed. IL-4 and IL-10 formed an integral and stable part of the regulatory component. In RA, the cytokine network underwent a dramatic reorganization caused by systemic inflammation. The network architecture became significantly more complex and fragmented, with the formation of four highly stable modules. The first was composed of IL-1β and TNF-α; the second included the cytokines of the IL-17A, IL-17F, and IL-23 axis; the third included IL-6 and IFN-γ; and the fourth included IL-4, IL-10, IL-31, IL-33, and sCD 40L. Analysis of the cytokine hyperproduction diagram revealed the IL-33 cluster. In patients seronegative for IgM RF, four modules are formed. The first is formed by IL-17A, IL-23, IL-25, and IL-17F; the second by IL-1β and IFN-γ; the third includes IL-33, IL-6, and IL-10; and the fourth includes TNF-α, IL-31, sCD 40L, and IL-4. In the IgM RF-seropositive variant of RA, the network architecture became significantly more complex and fragmented. A greater number of modules were identified. The first was formed by IL-23 and IL-17F; the second by IL-1β, IL-25, and IL-17A. TNF-α was embedded in each of them. The third module included IFN-γ and IL-6, the fourth – IL-31 and sCD 40L, the fifth – IL-33 and IL-4. IL-10 is more similar to the first two. In the patient groups with and without ACCP, the component architecture was similar for both the seronegative and IgM RF-seropositive variants of the disease, with minimal differences. The most pronounced and clear differences between the compared groups were obtained when analyzing the patient groups with and without IgM RF and/or ACCP. Conclusions . The results of cluster analysis demonstrate significant differences in the cytokine network architecture in RA compared to the control group, with the identification of a distinct IL-33 cluster. Differences are also observed between seronegative and seropositive subtypes of the disease.
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Cytokine clusters in rheumatoid arthritis: pathogenetic parallels
An imbalance in the production of pro- and anti-inflammatory cytokines plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Seropositivity for IgM rheumatoid factor (RF) and/or antibodies to cyclic citrullinated peptides (ACCP) determines disease subtypes. The aim of the study . To conduct a cluster analysis of the profile of pro- and anti-inflammatory cytokines detected in the blood serum of RA patients with an advanced stage of the disease in comparison with healthy individuals, the presence of IgM RF and ACCP in patients. Materials and methods . The study included 154 RA patients (41 men and 113 women of middle age 56.0 [50.0; 64.0] years), disease duration 9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM RF and/or 106 (68.8 %) ACCP with moderate or high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. Serum concentrations of interleukins (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ) and soluble CD 40 ligand (sCD 40L) were determined using multiplex technology. Hierarchical clustering of cytokines was performed in 20 healthy individuals and RA patients using Ward’s method. In RA, a comparison was made between seronegative and seropositive groups for IgM RF/ACCP. Results . In healthy individuals, the cytokine network exhibited a physiological organization. Cytokines were grouped into compact, well-defined modules with minimal cross-links between individual components. A dominant proinflammatory core of cytokines was absent, and a balanced cytokine network was observed. IL-4 and IL-10 formed an integral and stable part of the regulatory component. In RA, the cytokine network underwent a dramatic reorganization caused by systemic inflammation. The network architecture became significantly more complex and fragmented, with the formation of four highly stable modules. The first was composed of IL-1β and TNF-α; the second included the cytokines of the IL-17A, IL-17F, and IL-23 axis; the third included IL-6 and IFN-γ; and the fourth included IL-4, IL-10, IL-31, IL-33, and sCD 40L. Analysis of the cytokine hyperproduction diagram revealed the IL-33 cluster. In patients seronegative for IgM RF, four modules are formed. The first is formed by IL-17A, IL-23, IL-25, and IL-17F; the second by IL-1β and IFN-γ; the third includes IL-33, IL-6, and IL-10; and the fourth includes TNF-α, IL-31, sCD 40L, and IL-4. In the IgM RF-seropositive variant of RA, the network architecture became significantly more complex and fragmented. A greater number of modules were identified. The first was formed by IL-23 and IL-17F; the second by IL-1β, IL-25, and IL-17A. TNF-α was embedded in each of them. The third module included IFN-γ and IL-6, the fourth – IL-31 and sCD 40L, the fifth – IL-33 and IL-4. IL-10 is more similar to the first two. In the patient groups with and without ACCP, the component architecture was similar for both the seronegative and IgM RF-seropositive variants of the disease, with minimal differences. The most pronounced and clear differences between the compared groups were obtained when analyzing the patient groups with and without IgM RF and/or ACCP. Conclusions . The results of cluster analysis demonstrate significant differences in the cytokine network architecture in RA compared to the control group, with the identification of a distinct IL-33 cluster. Differences are also observed between seronegative and seropositive subtypes of the disease.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Impact of olokizumab on pain, patient global assessment of disease activity, functional impairment, and fatigue in patients with rheumatoid arthritis: A meta-analysis of randomized and observational studies
Olokizumab (OKZ) is a monoclonal antibody that binds interleukin 6 in the blood plasma, thereby exerting a pronounced anti-inflammatory effect in rheumatoid arthritis (RA). In addition to its effect on RA disease activity, OKZ significantly reduces the severity of key RA symptoms, which are referred to as patient-reported outcomes (PROs). The aim – to evaluate the effect of olokizumab on patient-reported outcomes using data from a meta-analysis of randomized controlled trials (RCTs) and observational studies. Materials and methods : We searched PubMed, Web of Science, Scopus, Cochrane, and eLibrary for publications from January 2014 to June 2025 using the keywords “olokizumab”, “rheumatoid arthritis”, and “patient-reported outcomes”: pain, PtGA, HAQ-DI, and FACIT-F. A meta-analysis was then conducted of a series of studies that met the selection criteria. In addition to the effect of OKZ on RA disease activity, it also examined its effect on PROs: pain (visual analog scale, 0–100 numeric rating scale), patient global assessment (PtGA), functional impairment (HAQ-DI (Health Assessment Questionnaire – Disability Index)), and fatigue (FACIT-F (Functional Assessment of Chronic Illness Therapy – Fatigue)). The efficacy of OKZ in the most commonly used regimen – subcutaneous injections of 64 mg every 4 weeks – was assessed. Results . Five phase II–III RCTs and four observational studies in real-world clinical practice (n=3013) were selected for the meta-analysis. According to the data obtained, significant positive dynamics in PROs were observed after 12 and 24 weeks from the start of therapy with OKZ treatment. Thus, pain dynamics by 24 weeks (mean difference) was –33.29 (95% confidential interval (95% CI): –39.53; –27.07), PtGA dynamics at 24 weeks was –28.62 (95% CI: –33.87; –23.37), HAQ-DI dynamics at 12 weeks was –0.24 (95% CI: –0.35; –0.13), and FACIT-F at 24 weeks was 8.80 (95% CI: 5.81; 11.79). The data obtained had moderate to high heterogeneity (I2 index >25%). The dynamics of PROs in RCTs and observational studies were unidirectional and similar. Conclusion. OKZ has a significant positive effect on PROs in RA. OKZ can be considered as an effective treatment for patients with RA, chronic pain, and fatigue.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Impact of olokizumab on pain, patient global assessment of disease activity, functional impairment, and fatigue in patients with rheumatoid arthritis: A meta-analysis of randomized and observational studies
Olokizumab (OKZ) is a monoclonal antibody that binds interleukin 6 in the blood plasma, thereby exerting a pronounced anti-inflammatory effect in rheumatoid arthritis (RA). In addition to its effect on RA disease activity, OKZ significantly reduces the severity of key RA symptoms, which are referred to as patient-reported outcomes (PROs). The aim – to evaluate the effect of olokizumab on patient-reported outcomes using data from a meta-analysis of randomized controlled trials (RCTs) and observational studies. Materials and methods : We searched PubMed, Web of Science, Scopus, Cochrane, and eLibrary for publications from January 2014 to June 2025 using the keywords “olokizumab”, “rheumatoid arthritis”, and “patient-reported outcomes”: pain, PtGA, HAQ-DI, and FACIT-F. A meta-analysis was then conducted of a series of studies that met the selection criteria. In addition to the effect of OKZ on RA disease activity, it also examined its effect on PROs: pain (visual analog scale, 0–100 numeric rating scale), patient global assessment (PtGA), functional impairment (HAQ-DI (Health Assessment Questionnaire – Disability Index)), and fatigue (FACIT-F (Functional Assessment of Chronic Illness Therapy – Fatigue)). The efficacy of OKZ in the most commonly used regimen – subcutaneous injections of 64 mg every 4 weeks – was assessed. Results . Five phase II–III RCTs and four observational studies in real-world clinical practice (n=3013) were selected for the meta-analysis. According to the data obtained, significant positive dynamics in PROs were observed after 12 and 24 weeks from the start of therapy with OKZ treatment. Thus, pain dynamics by 24 weeks (mean difference) was –33.29 (95% confidential interval (95% CI): –39.53; –27.07), PtGA dynamics at 24 weeks was –28.62 (95% CI: –33.87; –23.37), HAQ-DI dynamics at 12 weeks was –0.24 (95% CI: –0.35; –0.13), and FACIT-F at 24 weeks was 8.80 (95% CI: 5.81; 11.79). The data obtained had moderate to high heterogeneity (I2 index >25%). The dynamics of PROs in RCTs and observational studies were unidirectional and similar. Conclusion. OKZ has a significant positive effect on PROs in RA. OKZ can be considered as an effective treatment for patients with RA, chronic pain, and fatigue.
- Open Access
- 25 March 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 3 (1) , 49-58
Clinical indices and laboratory markers for evaluating the immune-mediated inflammation in rheumatoid arthritis: the impact of COVID-19
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease of unknown etiology that represents a considerable burden for both the patient and the healthcare system. The degree to which inflammation is being controlled determines the prognosis; therefore, achieving remission or low disease activity is of paramount importance to medical practitioners. The effectiveness of the currently employed treatment regimen for a specific patient is determined by the disease activity indices and the change in their values during treatment. The commonly used RA disease activity indices are the result of a painstaking search for the optimal set of clinical, laboratory and instrumental parameters reflecting the underlying pathogenesis of inflammation in RA spanning half a century. Routine laboratory tests not included in these indices can nevertheless provide additional valuable information regarding the disease. The new coronavirus infection, COVID-19, has similar pathogenetic mechanisms with immunoinflammatory rheumatic diseases, and its clinical and laboratory consequences in the form of postcovid-19 syndrome, make it difficult to assess the activity of RA using existing activity indices, raise the question of the need to take them into account when assessing the effectiveness and choosing the tactics of treatment of a patient with RA.
- 25 March 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 3 (1) , 49-58
Open AccessClinical indices and laboratory markers for evaluating the immune-mediated inflammation in rheumatoid arthritis: the impact of COVID-19
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease of unknown etiology that represents a considerable burden for both the patient and the healthcare system. The degree to which inflammation is being controlled determines the prognosis; therefore, achieving remission or low disease activity is of paramount importance to medical practitioners. The effectiveness of the currently employed treatment regimen for a specific patient is determined by the disease activity indices and the change in their values during treatment. The commonly used RA disease activity indices are the result of a painstaking search for the optimal set of clinical, laboratory and instrumental parameters reflecting the underlying pathogenesis of inflammation in RA spanning half a century. Routine laboratory tests not included in these indices can nevertheless provide additional valuable information regarding the disease. The new coronavirus infection, COVID-19, has similar pathogenetic mechanisms with immunoinflammatory rheumatic diseases, and its clinical and laboratory consequences in the form of postcovid-19 syndrome, make it difficult to assess the activity of RA using existing activity indices, raise the question of the need to take them into account when assessing the effectiveness and choosing the tactics of treatment of a patient with RA.
- Open Access
- 3 February 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (4) , 82-93
Erythrocytic indices of clinical blood analysis and reference intervals among men and women aged 18–45 years
Relevance. The determination of reference intervals (RI) in clinical blood analysis for erythrocytes and their specific parameters: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), allows us to use these parameters for differential diagnostics of various pathological conditions from variants of norm.Objective. Calculate the RI for erythrocyte parameters of a complete blood count for patients in a certain age group (18– 45 years) with normal indicators of iron homeostasis. The reference ranges may vary depending on the analytical systems and diagnostic reagents used.Material and methods. The study included blood samples from 158 healthy volunteers aged 18–45 years, of whom 127 (80.4 %) were women and 31 (19.6 %) were men. The data were obtained from the «KDL-TEST» company database for the period from 01.01.2023 to 01.01.2024. The criteria for inclusion in the study were: age from 18 to 45 years, clinical blood test results, and iron homeostasis within the RI of the «KDL-TEST» laboratory, absence of signs of an inflammatory process based on normal levels of C-reactive protein (CRP). Analyses were performed using a hematological analyzer Mindray BC- 6800 (manufactured by Mindray, China) and an automatic biochemical analyzer model AU-5800 (Beckman Coulter, USA) using IRON reagents (Beckman Coulter, USA) for the photometric colorimetric method and CRP-latex (Beckman Coulter, USA) immunoturbidimetric method.Results. The studies revealed a decrease in the upper limit of the RI for red blood cells (RBC) and their indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in women compared with the RI of the Russian National Standard (2009), which amounted to 4 % for the number of red blood cells, 5 % for hemoglobin, 2 % for hematocrit, 3.8 % for MCV and 3.5 % for MCH, as well as 4.2 % for MCHC; and a decrease in the upper limit of the RI of erythrocytes and erythrocyte indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in relation to the RI of the Russian National Standard (2009) in men for erythrocytes by 3.9 %, hemoglobin by 4, 6 %, MCV — by 1.9 %, MCH — by 4 %, MCHC — by 5.8 %. No significant differences were found in the values of erythrocytes and their specific parameters, hemoglobin, and hematocrit, between the data of the hematology analyzers Mindray BC-6800 and Sysmex XE series (p >0.05).Conclusions. A decrease in the RI of clinical blood analysis in women and men for some hemogram parameters (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in comparison with the RI of clinical blood analysis of the Russian National Standard (2009), which are within the generally accepted statistically acceptable deviations, was found. The use of automated hematology analyzers did not significantly affect the RI of erythrocytes or their specific parameters.
- 3 February 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (4) , 82-93
Open AccessErythrocytic indices of clinical blood analysis and reference intervals among men and women aged 18–45 years
Relevance. The determination of reference intervals (RI) in clinical blood analysis for erythrocytes and their specific parameters: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), allows us to use these parameters for differential diagnostics of various pathological conditions from variants of norm.Objective. Calculate the RI for erythrocyte parameters of a complete blood count for patients in a certain age group (18– 45 years) with normal indicators of iron homeostasis. The reference ranges may vary depending on the analytical systems and diagnostic reagents used.Material and methods. The study included blood samples from 158 healthy volunteers aged 18–45 years, of whom 127 (80.4 %) were women and 31 (19.6 %) were men. The data were obtained from the «KDL-TEST» company database for the period from 01.01.2023 to 01.01.2024. The criteria for inclusion in the study were: age from 18 to 45 years, clinical blood test results, and iron homeostasis within the RI of the «KDL-TEST» laboratory, absence of signs of an inflammatory process based on normal levels of C-reactive protein (CRP). Analyses were performed using a hematological analyzer Mindray BC- 6800 (manufactured by Mindray, China) and an automatic biochemical analyzer model AU-5800 (Beckman Coulter, USA) using IRON reagents (Beckman Coulter, USA) for the photometric colorimetric method and CRP-latex (Beckman Coulter, USA) immunoturbidimetric method.Results. The studies revealed a decrease in the upper limit of the RI for red blood cells (RBC) and their indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in women compared with the RI of the Russian National Standard (2009), which amounted to 4 % for the number of red blood cells, 5 % for hemoglobin, 2 % for hematocrit, 3.8 % for MCV and 3.5 % for MCH, as well as 4.2 % for MCHC; and a decrease in the upper limit of the RI of erythrocytes and erythrocyte indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in relation to the RI of the Russian National Standard (2009) in men for erythrocytes by 3.9 %, hemoglobin by 4, 6 %, MCV — by 1.9 %, MCH — by 4 %, MCHC — by 5.8 %. No significant differences were found in the values of erythrocytes and their specific parameters, hemoglobin, and hematocrit, between the data of the hematology analyzers Mindray BC-6800 and Sysmex XE series (p >0.05).Conclusions. A decrease in the RI of clinical blood analysis in women and men for some hemogram parameters (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in comparison with the RI of clinical blood analysis of the Russian National Standard (2009), which are within the generally accepted statistically acceptable deviations, was found. The use of automated hematology analyzers did not significantly affect the RI of erythrocytes or their specific parameters.
- 12 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 29,p. 68-74
The main pro- and antiinflammatory cytokines in rheumatoid arthritis: interrelationships and pathogenetic significance
Imbalance in the production of pro- and anti-inflammatory cytokines plays an important role in the pathogenesis of rheumatoid arthritis (RA). The aim of the study. To determine the concentration and frequency of increase in serum of pro- and anti-inflammatory cytokines in patients with RA in the advanced stage of the disease, assessment of the relationship between them, clinical and laboratory activity of the disease and autoantibodies. Materials and methods. We examined 154 RA patients (41 men and 113) women, of average age (56.0 [50.0; 64.0] years), disease duration (9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM rheumatoid factor (RF) and/or 106 (68.8 %) antibodies to cyclic citrullinated peptides (ACCP) with moderate to high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. The concentration of interleukin (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ), soluble CD 40 ligand (sCD 40L) in serum was determined by multiplex technology. Results. In RA patients, the concentration of IL-6, IL-23, IL-31, IL-33 and INF-γ was significantly higher, and TNF-α values were significantly lower than in controls. The levels of IL-1β, IL-17A, IL-17F, IL-25 and sCD 40L were not different from donors. IL-10 values were significantly higher than donors, and IL-4 values were not different from controls. In RA, the frequency of IL-33 elevation was 87.0 %, IL-6 51.6 %, IL-31 48.1 %, IL-17F 46.1 %, IL-23 42.9 % and INF-γ 39.0 %, IL-17A 29.9 %, IL-1β 26.6 %, TNF-α 23.4 %, IL-25 11.7 % and sCD 40L 3.2 % of patients. IL-33 hyperproduction was significantly predominant over other cytokines (p < 0.001). Elevated values of IL-10 were found in 16.2 % and IL-4 in 12.3 % of patients. Hyperproduction of proinflammatory cytokines, except IL-25 and sCD 40L, significantly prevailed over IL-4 and IL-10. Correlations of proinflammatory cytokines among themselves and with IL-4 and IL-10 were found. High values of IL-33 were associated only with IL-31. IL-4 and IL-10 concentrations were significantly correlated with each other. IL-6 concentration was found to be associated with DAS 28-ESR, CDAI and SDAI; IL-25 and sCD 40L were associated with CDAI and SDAI; IL-17A and IL-33 were associated with SDAI; IL-4 and IL-10, with CDAI and SDAI; IL-31 and IL-33, with CRP; TNF-α and INF-γ, with CRP; IL-17A, and IgM RF and ACCP; IL-31 and INF-γ, with IgM RF. IL-4 and IL10 were positively correlated with IgM RF, and IL-4 was negatively correlated with ADCP. Conclusions. In RA patients in the advanced stage of the disease, there is an imbalance between pro- and anti-inflammatory cytokines, with a predominance of IL-33 production. Despite the presence of interrelationships between cytokines, there are significant differences between them in associations with clinical indices, laboratory indicators of disease activity and autoantibodies.
- 12 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 29,p. 68-74
The main pro- and antiinflammatory cytokines in rheumatoid arthritis: interrelationships and pathogenetic significance
Imbalance in the production of pro- and anti-inflammatory cytokines plays an important role in the pathogenesis of rheumatoid arthritis (RA). The aim of the study. To determine the concentration and frequency of increase in serum of pro- and anti-inflammatory cytokines in patients with RA in the advanced stage of the disease, assessment of the relationship between them, clinical and laboratory activity of the disease and autoantibodies. Materials and methods. We examined 154 RA patients (41 men and 113) women, of average age (56.0 [50.0; 64.0] years), disease duration (9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM rheumatoid factor (RF) and/or 106 (68.8 %) antibodies to cyclic citrullinated peptides (ACCP) with moderate to high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. The concentration of interleukin (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ), soluble CD 40 ligand (sCD 40L) in serum was determined by multiplex technology. Results. In RA patients, the concentration of IL-6, IL-23, IL-31, IL-33 and INF-γ was significantly higher, and TNF-α values were significantly lower than in controls. The levels of IL-1β, IL-17A, IL-17F, IL-25 and sCD 40L were not different from donors. IL-10 values were significantly higher than donors, and IL-4 values were not different from controls. In RA, the frequency of IL-33 elevation was 87.0 %, IL-6 51.6 %, IL-31 48.1 %, IL-17F 46.1 %, IL-23 42.9 % and INF-γ 39.0 %, IL-17A 29.9 %, IL-1β 26.6 %, TNF-α 23.4 %, IL-25 11.7 % and sCD 40L 3.2 % of patients. IL-33 hyperproduction was significantly predominant over other cytokines (p < 0.001). Elevated values of IL-10 were found in 16.2 % and IL-4 in 12.3 % of patients. Hyperproduction of proinflammatory cytokines, except IL-25 and sCD 40L, significantly prevailed over IL-4 and IL-10. Correlations of proinflammatory cytokines among themselves and with IL-4 and IL-10 were found. High values of IL-33 were associated only with IL-31. IL-4 and IL-10 concentrations were significantly correlated with each other. IL-6 concentration was found to be associated with DAS 28-ESR, CDAI and SDAI; IL-25 and sCD 40L were associated with CDAI and SDAI; IL-17A and IL-33 were associated with SDAI; IL-4 and IL-10, with CDAI and SDAI; IL-31 and IL-33, with CRP; TNF-α and INF-γ, with CRP; IL-17A, and IgM RF and ACCP; IL-31 and INF-γ, with IgM RF. IL-4 and IL10 were positively correlated with IgM RF, and IL-4 was negatively correlated with ADCP. Conclusions. In RA patients in the advanced stage of the disease, there is an imbalance between pro- and anti-inflammatory cytokines, with a predominance of IL-33 production. Despite the presence of interrelationships between cytokines, there are significant differences between them in associations with clinical indices, laboratory indicators of disease activity and autoantibodies.
- Open Access
- 31 October 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (3) , 13-20
Classical proinflammatory cytokines in patients with rheumatoid arthritis: immunologic and clinical relationships
Relevance. Activation of innate and acquired immunity, accompanied by increased production of classical (interleukin (IL) IL-1β, IL-6, tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ)) proinflammatory cytokines in synovial fluid and blood serum, plays an important role in the pathogenesis of rheumatoid arthritis (RA).Objective. To determine the concentration of IL-1β, IL-6, TNF-α and INF-γ in RA patients in the advanced stage of the disease, to evaluate the relationship between them, clinical indices of disease activity, the presence of rheumatoid factor (RF), and antibodies to cyclic citrullinated peptide (ACCP).Material and methods. We examined 154 patients with RA (41 men and 113) who were middle-aged (56.0 (50.0; 64.0) years), disease duration (9.4 (3.0; 13.0) years), seropositive 129 (83.8 %) for IgM RF and/or 106 (68.8 %) ACCP with moderate to high (DAS28-ESR — 5.40 (4.65; 6.00)) disease activity. The concentration of IL-1β, IL-6, TNF-α and INF-γ in serum determined by multiplex technology.Results. The concentration of IL-1β was not significantly different between patients with RA and controls. The values of IL-6 and INF-γ were significantly higher, and TNF-α — significantly lower than in donors. IL-6 hyperproduction was detected most frequently (51.6 %), whereas elevated levels of INF-γ (38.96 %), IL-1β (26.62 %) and TNF-α (23.38 %) were less common. Significant positive correlations were observed between the concentrations of all cytokines and their high levels. The strongest correlations were characteristic for IL-1β, TNF-α and INF-γ. No statistically significant differences in cytokine levels were observed between patients with RA who were positive or negative for IgM-RF and ACCP. The concentration of IL-6 alone significantly positively correlated with the values of the indices (DAS28-ESR, CDAI, SDAI) of RA clinical activity (pConclusions. There are differences in the levels and frequencies of proinflammatory cytokines among patients with advanced-stage RA. In the presence of a close relationship between them, there are certain differences in their associations with clinical and laboratory indicators of disease activity.
- 31 October 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (3) , 13-20
Open AccessClassical proinflammatory cytokines in patients with rheumatoid arthritis: immunologic and clinical relationships
Relevance. Activation of innate and acquired immunity, accompanied by increased production of classical (interleukin (IL) IL-1β, IL-6, tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ)) proinflammatory cytokines in synovial fluid and blood serum, plays an important role in the pathogenesis of rheumatoid arthritis (RA).Objective. To determine the concentration of IL-1β, IL-6, TNF-α and INF-γ in RA patients in the advanced stage of the disease, to evaluate the relationship between them, clinical indices of disease activity, the presence of rheumatoid factor (RF), and antibodies to cyclic citrullinated peptide (ACCP).Material and methods. We examined 154 patients with RA (41 men and 113) who were middle-aged (56.0 (50.0; 64.0) years), disease duration (9.4 (3.0; 13.0) years), seropositive 129 (83.8 %) for IgM RF and/or 106 (68.8 %) ACCP with moderate to high (DAS28-ESR — 5.40 (4.65; 6.00)) disease activity. The concentration of IL-1β, IL-6, TNF-α and INF-γ in serum determined by multiplex technology.Results. The concentration of IL-1β was not significantly different between patients with RA and controls. The values of IL-6 and INF-γ were significantly higher, and TNF-α — significantly lower than in donors. IL-6 hyperproduction was detected most frequently (51.6 %), whereas elevated levels of INF-γ (38.96 %), IL-1β (26.62 %) and TNF-α (23.38 %) were less common. Significant positive correlations were observed between the concentrations of all cytokines and their high levels. The strongest correlations were characteristic for IL-1β, TNF-α and INF-γ. No statistically significant differences in cytokine levels were observed between patients with RA who were positive or negative for IgM-RF and ACCP. The concentration of IL-6 alone significantly positively correlated with the values of the indices (DAS28-ESR, CDAI, SDAI) of RA clinical activity (pConclusions. There are differences in the levels and frequencies of proinflammatory cytokines among patients with advanced-stage RA. In the presence of a close relationship between them, there are certain differences in their associations with clinical and laboratory indicators of disease activity.
- Open Access
- 23 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (10) , e15320
Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study
Aim: Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.Methods: An open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow‐up period was 24 weeks or less. RA activity (DAS28‐CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT‐F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.Results: The study cohort was comprised of 144 patients. And 39 patients were lost to follow‐up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28‐CRP decreased to 3.3 ± 0.9 (p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration (p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% (p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% (р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.Conclusion: OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.
- 23 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (10) , e15320
Open AccessOlokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study
Aim: Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.Methods: An open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow‐up period was 24 weeks or less. RA activity (DAS28‐CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT‐F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.Results: The study cohort was comprised of 144 patients. And 39 patients were lost to follow‐up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28‐CRP decreased to 3.3 ± 0.9 (p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration (p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% (p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% (р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.Conclusion: OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.
- Open Access
- 20 October 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (5) , 54-64
Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods. A retrospective cohort study conducted in 11 centers in the Russian Federation included 110 patients with confirmed diagnosis of RA according to 2010 ACR/EULAR criteria. In all patients in early 2022 (due to problems with drug supply during the coronavirus pandemic) iIL6R were switched for non-medical reasons to OKZ at a dose of 64 mg once every 2 weeks or once every 4 weeks in accordance with the instructions for the medical use of OKZ.Data on clinical efficacy, safety and changes in the dosing regimen of the drugs over an observation period of one year are presented. We assessed the dynamics of the clinical indicators: number of painful and swollen joints, pain on a visual analogue scale and DAS28-ESR/CRP indices. Routine laboratory tests included assessment of red and white blood cells count, ESR, hemoglobin, CRP, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and cholesterol. Adverse events (AEs) were recorded in accordance with standard practice.Results and discussion. After 6 months of therapy, the proportion of patients who achieved remission/low disease activity according to DAS28-ESR and DAS28-CRP decreased to 70.1% and 72.9%, respectively, and the proportion of patients with moderate and high activity according to DAS28-ESR increased to 26.1% and 3.7%, respectively, and according to DAS28-CRP to 21.5% and 5.6 %, respectively. After 12 months, remission/low disease activity according to DAS28-ESR and DAS28-CRP was achieved in 81.4% and 83.5% of patients, respectively, and 18.6% and 16.5% of patients had moderate activity.In the OKZ monotherapy group, after 6 months of treatment 22 (71.0%) patients were in remission/low disease activity according to DAS28-ESR and 23 (74.2%) patients according to DAS28-CRP. After one year of observation, remission/low disease activity according to DAS28-ESR and DAS28-CRP had 24 (88.9%) and 23 (85.2%) patients, respectively.In the combined therapy group of OKZ + disease-modifying antirheumatic drugs (DMARDs), remission/low disease activity according to DAS28-ESR was observed in 53 (70.7%) patients and according to DAS28-CRP – in 55 (73.3%) patients by the 6th month of therapy. After 12 months, in this group 55 (78.6%) patients showed remission/low disease activity according to DAS28-ESR and according to DAS28-CRP – 58 (82.9 %) patients.After 6 months, 107 (97.3 %) out of 110 patients included in the study continued treatment. In 1 (0.9%) case OKZ was discontinued due to insufficient effect, in 2 cases contact with the patients was lost. After 12 months, therapy was continued in 97 (88.2%) patients. In 5 (4.5%) cases treatment was discontinued due to insufficient efficacy, in 2 (1.8%) cases – due to increased AST/ALT levels, in another 2 (1.8 %) cases – for non-medical reasons, and in 1 case contact with the patient was lost.Conclusion. OKZ, a direct IL-6 inhibitor, provided effective control over RA symptoms after switching from iIL6R, which allowed to achieve the treatment goal of maintaining remission/low disease activity over 1 year in more than 80% of patients. OKZ has demonstrated a broad spectrum of capabilities in real-world clinical practice, even when used as monotherapy. In terms of safety profile, OKZ was comparable to other IL6 inhibitors.
- 20 October 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (5) , 54-64
Open AccessSwitching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods. A retrospective cohort study conducted in 11 centers in the Russian Federation included 110 patients with confirmed diagnosis of RA according to 2010 ACR/EULAR criteria. In all patients in early 2022 (due to problems with drug supply during the coronavirus pandemic) iIL6R were switched for non-medical reasons to OKZ at a dose of 64 mg once every 2 weeks or once every 4 weeks in accordance with the instructions for the medical use of OKZ.Data on clinical efficacy, safety and changes in the dosing regimen of the drugs over an observation period of one year are presented. We assessed the dynamics of the clinical indicators: number of painful and swollen joints, pain on a visual analogue scale and DAS28-ESR/CRP indices. Routine laboratory tests included assessment of red and white blood cells count, ESR, hemoglobin, CRP, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and cholesterol. Adverse events (AEs) were recorded in accordance with standard practice.Results and discussion. After 6 months of therapy, the proportion of patients who achieved remission/low disease activity according to DAS28-ESR and DAS28-CRP decreased to 70.1% and 72.9%, respectively, and the proportion of patients with moderate and high activity according to DAS28-ESR increased to 26.1% and 3.7%, respectively, and according to DAS28-CRP to 21.5% and 5.6 %, respectively. After 12 months, remission/low disease activity according to DAS28-ESR and DAS28-CRP was achieved in 81.4% and 83.5% of patients, respectively, and 18.6% and 16.5% of patients had moderate activity.In the OKZ monotherapy group, after 6 months of treatment 22 (71.0%) patients were in remission/low disease activity according to DAS28-ESR and 23 (74.2%) patients according to DAS28-CRP. After one year of observation, remission/low disease activity according to DAS28-ESR and DAS28-CRP had 24 (88.9%) and 23 (85.2%) patients, respectively.In the combined therapy group of OKZ + disease-modifying antirheumatic drugs (DMARDs), remission/low disease activity according to DAS28-ESR was observed in 53 (70.7%) patients and according to DAS28-CRP – in 55 (73.3%) patients by the 6th month of therapy. After 12 months, in this group 55 (78.6%) patients showed remission/low disease activity according to DAS28-ESR and according to DAS28-CRP – 58 (82.9 %) patients.After 6 months, 107 (97.3 %) out of 110 patients included in the study continued treatment. In 1 (0.9%) case OKZ was discontinued due to insufficient effect, in 2 cases contact with the patients was lost. After 12 months, therapy was continued in 97 (88.2%) patients. In 5 (4.5%) cases treatment was discontinued due to insufficient efficacy, in 2 (1.8%) cases – due to increased AST/ALT levels, in another 2 (1.8 %) cases – for non-medical reasons, and in 1 case contact with the patient was lost.Conclusion. OKZ, a direct IL-6 inhibitor, provided effective control over RA symptoms after switching from iIL6R, which allowed to achieve the treatment goal of maintaining remission/low disease activity over 1 year in more than 80% of patients. OKZ has demonstrated a broad spectrum of capabilities in real-world clinical practice, even when used as monotherapy. In terms of safety profile, OKZ was comparable to other IL6 inhibitors.
- Open Access
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 402–407
IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis
ИЛ-17А, ИЛ-17F и ИЛ-23 у больных ревматоидным артритом
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 402–407
Open AccessIL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis
ИЛ-17А, ИЛ-17F и ИЛ-23 у больных ревматоидным артритом
- 21 July 2024
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (10) , 31-36
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, pConclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.
- 21 July 2024
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (10) , 31-36
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, pConclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.